REGENXBIO CMO exercises options and sells stock

REGENXBIO Inc. Chief Medical Officer Steve Pakola reported exercising stock options for 36,725 shares of common stock at $7.8600 per share on July 1, 2026, then selling 36,725 shares at $12.8600 the same day and 19,608 shares at $11.0400 on June 29, 2026.

Rhea-AI Filing Summary

REGENXBIO Inc. Chief Medical Officer Steve Pakola reported exercising stock options for 36,725 shares of common stock at $7.8600 per share on July 1, 2026, then selling 36,725 shares at $12.8600 the same day and 19,608 shares at $11.0400 on June 29, 2026.

After these trades he directly holds 213,009 shares of common stock, and 66,973 stock options from the reported award remained outstanding. Footnotes state that at least one transaction was effected under a Rule 10b5-1 trading plan, that some sales were executed in multiple trades at weighted-average prices between $11.00 and $11.18, and that a previously granted option for 103,698 shares vests 25% on January 2, 2026 with the balance in equal monthly installments over 36 months while he continues in service.

Insights

Equity compensation and insider-trading analyst

Routine exercise-and-sell by REGENXBIO’s CMO with remaining sizable holdings.

Chief Medical Officer Steve Pakola exercised stock options for 36,725 REGENXBIO shares at $7.86 and sold 56,333 shares in open-market trades. This pattern reflects a typical liquidity event where options are converted into shares and partly monetized.

Following the transactions, he still directly owns 249,734 shares and 66,973 stock options expiring on January 2, 2035, indicating continued equity exposure. At least one sale occurred under a Rule 10b5-1 trading plan, which is pre-arranged and reduces the informational value of the trade’s timing for investors.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider PAKOLA STEVE

Role Chief Medical Officer

Sold 56,333 shs ($689K)

Approx. gross sale proceeds $689K

Approx. exercise cost $289K

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	36,725	$0.00	$0.00
Exercise	Common Stock	36,725	$7.86	$289K
Sale	Common Stock	36,725	$12.86	$472K
Sale	Common Stock	19,608	$11.04	$216K

Holdings After Transaction: Stock Options (Right to Buy) — 66,973 contracts (Direct); Common Stock — 213,009 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
2. F2. This transaction was executed in multiple trades at prices ranging from $11.00 to $11.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. F3. The previously granted option, representing a right to purchase a total of 103,698 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 2, 2026, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer

Key Figures

Options exercised: 36,725 shares Option exercise price: $7.8600 per share Shares sold July 1, 2026: 36,725 shares at $12.8600 per share +5 more

8 metrics

Options exercised 36,725 shares Stock options for common stock exercised on July 1, 2026

Option exercise price $7.8600 per share Exercise price for stock options exercised on July 1, 2026

Shares sold July 1, 2026 36,725 shares at $12.8600 per share Common stock sale reported for July 1, 2026

Shares sold June 29, 2026 19,608 shares at $11.0400 per share Common stock sale reported for June 29, 2026

Total shares sold 56,333 shares Aggregate common shares sold per transaction summary

Post-transaction common holdings 213,009 shares Direct common stock held after reported transactions

Remaining options in award 66,973 options Stock options remaining after the July 1, 2026 exercise

Previously granted option size 103,698 shares Shares covered by a previously granted option with staged vesting

Key Terms

Rule 10b5-1 trading plan, Stock Options (Right to Buy), weighted average sale price, vests in equal monthly installments

4 terms

Rule 10b5-1 trading plan financial

"This transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Options (Right to Buy) financial

"security_title "Stock Options (Right to Buy)" in the derivative line"

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

vests in equal monthly installments financial

"the balance vests in equal monthly installments over the 36 months thereafter"

FAQ

What insider trades did REGENXBIO (RGNX) report for Steve Pakola?

REGENXBIO’s Chief Medical Officer Steve Pakola exercised options for 36,725 shares at $7.8600 and sold 56,333 shares of common stock on June 29 and July 1, 2026, according to the reported Form 4 transactions.

How many REGENXBIO (RGNX) shares does Steve Pakola hold after these trades?

After the reported transactions, Steve Pakola directly holds 213,009 shares of REGENXBIO common stock. This post-transaction balance is provided in the holdings data and reflects his direct ownership following the June 29 and July 1, 2026 trades.

What were the sale prices in Steve Pakola’s REGENXBIO (RGNX) stock transactions?

Steve Pakola sold 36,725 shares at $12.8600 on July 1, 2026 and 19,608 shares at $11.0400 on June 29, 2026. A footnote adds that some sales occurred in multiple trades between $11.00 and $11.18 at a weighted average price.

Were Steve Pakola’s REGENXBIO (RGNX) trades under a Rule 10b5-1 plan?

A footnote states that at least one of Steve Pakola’s transactions was effected pursuant to a Rule 10b5-1 trading plan. This indicates that some trading activity followed a pre-established plan, though the specific transaction is not identified in the structured data.

What are the terms of Steve Pakola’s 103,698-share option at REGENXBIO (RGNX)?

A previously granted option representing 103,698 shares vests 25% on January 2, 2026, with the remaining shares vesting in equal monthly installments over 36 months, conditioned on Steve Pakola’s continuous service to REGENXBIO.

How many REGENXBIO (RGNX) stock options did Steve Pakola exercise and retain?

Steve Pakola exercised options covering 36,725 shares at $7.8600 per share on July 1, 2026. Following this exercise, 66,973 stock options from the reported award remained outstanding, based on the derivative position line in the Form 4 data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 08:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PAKOLA STEVE

(Last) (First) (Middle)

C/O REGENXBIO INC.

9804 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		S(1)		19,608	D	$11.04(2)	213,009	D
Common Stock	07/01/2026		M(1)		36,725	A	$7.86	249,734	D
Common Stock	07/01/2026		S(1)		36,725	D	$12.86	213,009	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$7.86	07/01/2026		M(1)			36,725	(3)	01/02/2035	Common Stock	36,725	$0.00	66,973	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan.

2. This transaction was executed in multiple trades at prices ranging from $11.00 to $11.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. The previously granted option, representing a right to purchase a total of 103,698 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 2, 2026, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer

Remarks:

	/s/ Patrick J. Christmas as attorney-in-fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)